Wednesday, July 8, 2026

Patent intelligence · US

US 11987821

Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

granted A61KA61K35/12A61K38/45A61K47/60
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 5
Patent details — US 11987821
Jurisdiction
US
Status
granted
Grant date
May 21, 2024
Expiration
May 16, 2044
Claims
18
CPC classes
A61K, A61K35/12, A61K38/45, A61K47/60
View on Google Patents ↗

Quick answer

US 11987821 (Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy) is held by Entrada Therapeutics, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K35/12, A61K38/45, A61K47/60, A61K47/645

More from Entrada Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11225506

    Cell penetrating peptides and methods of making and using thereof

    Entrada Therapeutics, Inc. · Expires Jan 13, 2042

    granted
  2. US 11168310

    Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy

    Entrada Therapeutics, Inc. · Expires Nov 4, 2041

    granted
  3. US 10815276

    Cell penetrating peptides and methods of making and using thereof

    Entrada Therapeutics, Inc. · Expires Oct 22, 2040

    granted
  4. US 10626147

    Cell penetrating peptides and methods of making and using thereof

    Entrada Therapeutics, Inc. · Expires Apr 16, 2040

    granted

Frequently asked questions

What is US patent 11987821?

US 11987821 (Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy) is held by Entrada Therapeutics, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11987821?

Entrada Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.

When does US 11987821 expire?

Our index shows an expiration date of May 16, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.